CLIENT NAME: SAMPLE REPORT

DOB:	SPECIMEN:	COLLECTED:	CLIENT NUMBER:
SEX:	REQUISITION:	RECEIVED:	
PATIENT ID:	REPORT STATUS:	REPORTED:	PRACTITIONER:

Test Name	In Range	Out Of Range	Reference Range
VON WILLEBRAND COMPREHENSIVE PANEL 2			
INTERPRETATION	SEE NOTE		

For further inquiries regarding specific clinical problems or coagulation laboratory test issues, please call a Quest Diagnostics Customer Support Representative, (800) 553-5445 for referral to the Medical Director of Coagulation.

For additional information, please refer to http://education.questdiagnostics.com/faq/FAQ08v1 (This link is being provided for informational/educational purposes only.)

PARTIAL THROMBOPLASTIN TIME, ACTIVATED	32		22-34 sec

This test has not been validated for monitoring unfractionated heparin therapy. For testing that is validated for this type of therapy, please refer to the Heparin Anti-Xa assay (test code 30292).

For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ159 (This link is being provided for informational/educational purposes only.)

FACTOR VIII ACTIVITY, CLOTTING		**44 L**	50-180 % normal

For additional information, please refer to http://education.questdiagnostics.com/faq/FAQ210 (This link is being provided for informational/educational purposes only.)

VON WILLEBRAND FACTOR ANTIGEN	57		50-217 %
RISTOCETIN COFACTOR	56		42-200 % normal
VON WILLEBRAND FACTOR COLLAGEN BINDING ASSAY			
VWF: COLLAGEN BINDING	45		45-198 % normal
RATIO (CBA/VW AG)	0.79		> OR = 0.50 ratio

A CBA:vWF AG ratio of <0.5 suggests a qualitative defect of von Willebrand Factor.

References:

1) Favaloro, EJ et. al. Discrimination of von Willebrand's disease (VWD) subtypes: direct comparison of von Willebrand factor: collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based vWF-capture systems. Thromb Haemost 2000;84:541-547.

VON WILLEBRAND ANTIGEN, MULTIMERIC ANALYSIS			
VWF AG, MULTIMERIC	SEE NOTE		NORMAL

All multimers of von Willebrand Factor Antigen are present in normal amounts.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1)	10		4-43 ng/mL

Elevated levels of PAI-1 are associated with risk of thrombotic stroke, myocardial infarction, and venous thrombosis. PAI-1 may be elevated in diabetes and pregnancy. Platelet contamination of a test sample will tend to falsely elevate results.